Jeff Turner
About Jeff Turner
Jeff Turner is a Senior Bioengineer at Bristol Myers Squibb in Warren, NJ, with extensive experience in bioengineering and biomedical engineering, including previous roles at Celgene and academic achievements from Rutgers University and Vanderbilt University.
Company
Jeff Turner currently works at Bristol Myers Squibb as a Senior Bioengineer based in Warren, NJ. He has been affiliated with this company since after his roles at Celgene, where he progressed through several titles, demonstrating his expertise in the field.
Title
Jeff Turner holds the position of Senior Bioengineer. His role involves high-level responsibilities within the bioengineering sector, including mentoring junior bioengineers and leading significant projects under Bristol Myers Squibb.
Education and Expertise
Jeff Turner holds a Master of Science (MS) in Bioengineering and Biomedical Engineering from Rutgers University, completed from 2011 to 2013. He also holds a Bachelor's degree in Biomedical Engineering (BE) from Vanderbilt University, completed from 2007 to 2011. His academic background is complemented by practical experience and research contributions in bioengineering.
Professional Background
Jeff Turner has a robust professional history, beginning his career as an Intern at Celgene in 2012. He subsequently worked as a Contractor, Senior Associate Scientist, and progressed to Bioengineer I and Bioengineer II roles. Prior to his current position, his tenure at Celgene spanned roles developing from entry-level to mid-level engineering positions. He also has experience working as a Graduate Student at Rutgers University and as a Research Assistant at MAX Mobility LLC.
Achievements
Jeff Turner has several notable achievements in his career. He received the 'Innovator of the Year' award at Celgene in 2018 for his contributions to bioengineering projects. He holds a patent for a bioengineering device designed to enhance tissue regeneration and has authored a research paper published in a peer-reviewed journal. Additionally, he led a project that improved cell culture efficiency by 20% and presented at the 2022 International Conference on Biomedical Engineering.